CoChat

Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial

Tan, Ai Huey, Lim, Shen‐Yang, Mahadeva, Sanjiv, Loke, Mun Fai, Tan, Jiun Yan, Ang, Ban Hong, Chin, Kok Ping, Mohammad Adnan, Amni Fatihah, Ong, Shawna Mei Chien, Ibrahim, Aimi Izzah, Zulkifli, Nusyaibah, Lee, Jing Kun, Lim, Wan Ting, Teo, Yong Teck, Kok, Yong Leng, Ng, Tze Ying, Tan, Aaron Guan Siang, Zulkifle, Intan Maisara, Ng, Chin Khoon, Ee, Soon Sean, Arafin, Shuhaina, Mohamad Shukori, Khairunnisa, Vadivelu, Jamunarani S., Marras, Connie, Fox, Susan H., Lang, Anthony E. · 2020 · Movement Disorders
Cited by 76

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: Helicobacter pylori (HP) infection has been associated with worse motor function in Parkinson's disease (PD). Objective: We aimed to evaluate the effects of HP eradication on PD symptoms. Methods: In this parallel‐group, double‐blind, randomized placebo‐controlled, single‐center trial, patients with PD with positive HP urea breath test and serology were block randomized (1:1) to receive standard eradication triple therapy or identically appearing placebo capsules for 1 week. Prespecified motor (International Parkinson and Movement Disorder Society Unified PD Rating Scale [MDS‐UPDRS], timed tests, and home‐based wearable sensor measurements), nonmotor (Leeds Dyspepsia Questionnaire and Montreal Cognitive Assessment), and quality‐of‐life (Parkinson's Disease Questionnaire‐39) outcome measures were assessed at weeks 6, 12, 24, and 52. The primary outcome was the baseline‐to‐week 12 change in ON medication MDS‐UPDRS motor scores. Lactulose‐hydrogen breath testing for concomitant small intestinal bacterial overgrowth was performed at baseline and repeated at week 24, together with the urea breath test. Results: A total of 310 patients were screened for eligibility and 80 were randomly assigned, of whom 67 were included in the full‐analysis set (32 treatment group patients, 35 placebo patients). HP eradication did not improve MDS‐UPDRS motor scores at week 12 (mean difference 2.6 points in favor of placebo, 95% confidence interval: −0.4 to 5.6, P = 0.089). There was no significant improvement in any motor, nonmotor, or quality‐of‐life outcome at weeks 12 and 52. Both the full‐analysis and per‐protocol analyses (based on eradication status) supported these conclusions. Small intestinal bacterial overgrowth status did not influence treatment results. Conclusions: HP eradication does not improve clinical outcomes in PD, suggesting that there is no justification for routine HP screening or eradication with the goal of improving PD symptoms. © 2020 International Parkinson and Movement Disorder Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.28248

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 76

Metadata

Authors
Tan, A. H., Lim, S., Mahadeva, S., Loke, M. F., Tan, J. Y., Ang, B. H., Chin, K. P., Mohammad Adnan, A. F., Ong, S. M. C., Ibrahim, A. I., Zulkifli, N., Lee, J. K., Lim, W. T., Teo, Y. T., Kok, Y. L., Ng, T. Y., Tan, A. G. S., Zulkifle, I. M., Ng, C. K., Ee, S. S., Arafin, S., Mohamad Shukori, K., Vadivelu, J. S., Marras, C., Fox, S. H., & Lang, A. E.
Venue
Movement Disorders
Publisher
Wiley
Published
2020-09-07
Volume
35
Issue
12
Pages
2250-2260
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
OpenAlex
W3084082471
Cited by
76
References
9
FWCI
3.99
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial. https://app.cochat.ai/papers/10.1002/mds.28248
The paper
Tan, A. H., Lim, S., Mahadeva, S., Loke, M. F., Tan, J. Y., Ang, B. H., Chin, K. P., Mohammad Adnan, A. F., Ong, S. M. C., Ibrahim, A. I., Zulkifli, N., Lee, J. K., Lim, W. T., Teo, Y. T., Kok, Y. L., Ng, T. Y., Tan, A. G. S., Zulkifle, I. M., Ng, C. K., . . . Lang, A. E. (2020). Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial. Movement Disorders. https://doi.org/10.1002/mds.28248

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.